Acquisition-Related Amortization and Remeasurement - Additional Information (Details) - USD ($) $ in Millions		1 Months Ended			3 Months Ended
	Dec. 29, 2022	May 31, 2022	Apr. 30, 2021	Feb. 28, 2021	Sep. 30, 2022	Dec. 31, 2022	Jul. 30, 2022
License Agreement [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront payment payable with additional payments							$ 1.4
Upfront payment					$ 1.4
Consideration agreed to pay with additional payments contingent upon reaching future commercialization and revenue-based milestones	$ 0.2
Initial payment accrued						$ 0.2
Contingent Payment Upon Reaching FDA Milestone			$ 4.0
Amount Received for the year		$ 1.5	$ 0.5
Contingent consideration milestone obligation		$ 3.5
License Agreement [Member] | Other Current Liabilities [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Contingent consideration accrued						1.0
License Agreement [Member] | Other Noncurrent Liabilities [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Contingent consideration accrued						$ 1.0
Intellectual Property Rights [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Consideration transferred				$ 1.0
Consideration transferred				$ 9.0
Maximum [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Royalty percentage on net sales				4.00%
Maximum [Member] | Intellectual Property Rights [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Consideration transferred				$ 10.0
Minimum [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Royalty percentage on net sales				2.00%